Supplementary Figure S6 from Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial
crossref(2023)
摘要
Distinct molecular subtypes as defined by the TCGA of GBM show a trend towards benefit from Beva/CCNU treatment.
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要